Garenoxacin
- CAS No.
- 194804-75-6
- Chemical Name:
- Garenoxacin
- Synonyms
- T 3811;T-3811;Aids080974;Aids-080974;Garenoxacin;Ganefloxacin;GARENOXACIN HBR;Garenoxacin USP/EP/BP;Garenoxacin (BMS-284756);Bms 284756 (*mesylate salt*)
- CBNumber:
- CB01504008
- Molecular Formula:
- C23H20F2N2O4
- Molecular Weight:
- 426.41
- MDL Number:
- MFCD08141853
- MOL File:
- 194804-75-6.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Product description | Number | Pack Size | Price |
| Garenoxacin ≥98% | 33599 | 5mg | $121 |
| Garenoxacin ≥98% | 33599 | 10mg | $182 |
| Garenoxacin ≥98% | 33599 | 25mg | $388 |
| Garenoxacin | 278310 | 1mg | $396 |
| Garenoxacin | 278310 | 2mg | $539 |
| More product size | |||
| Melting point | 226-227°; mp 234-235° |
|---|---|
| alpha | D27 -9.0° (c = 0.10 in N,N-dimethylformamide) |
| Boiling point | 581.5±50.0 °C(Predicted) |
| Density | 1.421±0.06 g/cm3(Predicted) |
| storage temp. | Hygroscopic, -20°C Freezer, Under inert atmosphere |
| solubility | DMF (Slightly, Heated), DMSO (Slightly, Heated), Methanol (Slightly, Heated) |
| form | Solid |
| pka | 6.44±0.50(Predicted) |
| color | Off-White to Pale Yellow |
| Stability | Hygroscopic |
| InChIKey | NJDRXTDGYFKORP-LLVKDONJSA-N |
| SMILES | N1(C2CC2)C2=C(C=CC(C3C=CC4=C(C=3)CN[C@@H]4C)=C2OC(F)F)C(=O)C(C(O)=O)=C1 |
| FDA UNII | V72H9867WB |
| ATC code | J01MA19 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |   GHS06,GHS08 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H301-H361 | |||||||||
| Precautionary statements | P201-P202-P264-P270-P280-P301+P310-P321-P330-P308+P313-P405-P501 | |||||||||
| NFPA 704 |
|
Garenoxacin price More Price(38)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 33599 | Garenoxacin ≥98% | 194804-75-6 | 5mg | $121 | 2026-04-30 | Buy |
| Cayman Chemical | 33599 | Garenoxacin ≥98% | 194804-75-6 | 10mg | $182 | 2026-04-30 | Buy |
| Cayman Chemical | 33599 | Garenoxacin ≥98% | 194804-75-6 | 25mg | $388 | 2026-04-30 | Buy |
| Usbiological | 278310 | Garenoxacin | 194804-75-6 | 1mg | $396 | 2026-06-03 | Buy |
| Usbiological | 278310 | Garenoxacin | 194804-75-6 | 2mg | $539 | 2026-06-03 | Buy |
Garenoxacin Chemical Properties,Uses,Production
Description
Garenoxacin is a new quinolone antimicrobial agent that exhibits a
broad spectrum of activity against both Gram-negative and Gram-positive
organisms, including the important community-acquired respiratory pathogens
S.pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. In addition, it has
potent activity against several resistant strains such as multidrug-resistant
S.pneumoniae, methicillin-resistant S.aureus (MRSA), and vancomycin-resistant
enterococci (VRE). It was launched in Japan as an oral treatment for respiratory tract and otorhinolaryngological infections. As with other quinolone antibiotics marketed in recent years, the mechanism of action of garenoxacin involves dual inhibition of two essential bacterial enzymes, DNA gyrase and topoisomerase IV. The lack of 6-fluoro substituent does not adversely affect its potency of inhibiting DNA gyrase (Escherichia coli, IC50 0.17 mg/mL) or topoisomerase IV (S. aureus, IC50 2.19 mg/ mL).
In human pharmacokinetic studies, oral garenoxacin results in dose-proportionate increases of plasma Cmax and AUC values at doses ranging from 50 to 1,200 mg. Its oral bioavailability is about 95%, and the mean terminal half-life is 15.4 h.
The most common adverse events associated with garenoxacin were rash, dizziness, nausea, headache, and pruritus. Garenoxacin is chemically derived in a sequence of 14 steps, 12 of which entail the construction of a key quinolone intermediate, 7-bromo-1- cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid ethyl ester. Subsequently, Suzuki cross-coupling reaction of this intermediate with (R)-[1-methyl-2-(trityl)isoindolin-5-yl]boronic acid, followed by deprotection of the trityl group and ester hydrolysis with hydrochloric acid gives garenoxacin. The chiral isoindoline reagent is obtained from racemic 5-bromo-2-methylisoindoline via coupling with N-CBZ-L-phenylalanine, separation of diastereomers by chromatography, cleavage of the chiral auxiliary, N-tritylation, halogen-metal exchange with butyllithium, and boronation with triisopropyl borate.
Originator
Toyama (Japan)
Uses
Des-F(6)-quinolone antibacterial; topoisomerase II inhibitor. Antibacterial.
Definition
ChEBI: A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid that is substituted by a cyclopropyl group at position 1, an oxo group at position 4, a (1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl group at po ition 7, and a difluoromethoxy group at position 8.
brand name
Geninax
Garenoxacin Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Hefei TianRui Pharmaceutical Chemical Co., Ltd. | +86-0551-68665055 +86-+86-18616906106 | sales@trywchem.com | China | 187 | 58 |
| Capot Chemical Co.,Ltd. | +86-（0）57185586718 +86-13336195806 | sales@capot.com | China | 29640 | 60 |
| Beijing Cooperate Pharmaceutical Co.,Ltd | 010-60279497 | sales01@cooperate-pharm.com | CHINA | 1803 | 55 |
| career henan chemical co | +86-0371-86658258 +8613203830695 | sales@coreychem.com | China | 29815 | 58 |
| Biochempartner | 0086-13720134139 | candy@biochempartner.com | CHINA | 965 | 58 |
| Alchem Pharmtech,Inc. | 8485655694 | sales@alchempharmtech.com | United States | 63687 | 58 |
| CONIER CHEM AND PHARMA LIMITED | +8618523575427 | sales@conier.com | China | 49979 | 58 |
| HANGZHOU CLAP TECHNOLOGY CO.,LTD | 86-571-88216897,88216896 13588875226 | sales@hzclap.com | CHINA | 6312 | 58 |
| Dideu Industries Group Limited | +86-29-89586680 +86-15129568250 | 1026@dideu.com | China | 20582 | 58 |
| Dayang Chem (Hangzhou) Co.,Ltd. | +86-0571-88938639 +8617705817739 | info@dycnchem.com | China | 52705 | 58 |
Related articles
- Toxicity of Garenoxacin
- Garenoxacin is a desfluoro quinolone which, as such, lacks a fluorine at the C-6 position in comparison with other fluoroquino....
- Mar 18，2022
View Lastest Price from Garenoxacin manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2025-12-05 | Garenoxacin
194804-75-6
|
1G | 99.99％ | 1KGS | Hefei TianRui Pharmaceutical Chemical Co., Ltd. | ||
 |
2025-11-18 | Garenoxacin USP/EP/BP
194804-75-6
|
$1.10 | 1g | 99.9% | 100 Tons min | Dideu Industries Group Limited | |
 |
2025-05-12 | Garenoxacin
194804-75-6
|
1kg | 98% HPLC | 500 kgs | PUSHAN INDUSTRIAL (SHAANXI) CO.,LTD |
-
- Garenoxacin
194804-75-6
- 99.99％
- Hefei TianRui Pharmaceutical Chemical Co., Ltd.
-
- Garenoxacin USP/EP/BP
194804-75-6
- $1.10
- 99.9%
- Dideu Industries Group Limited
-
- Garenoxacin
194804-75-6
- $0.00
- 98% HPLC
- PUSHAN INDUSTRIAL (SHAANXI) CO.,LTD
